Endocrine gland neoplasm

Summary

Endocrine gland neoplasm (MONDO:0002082) is a cancer (an umbrella term covering 14 Mondo subtypes) with 4 cohort genes (4 GWAS associations across 5 studies; 3 CIViC-evidence somatic drivers; 4 ClinVar predisposition records) and 25 clinical trials. Top therapeutic interventions include gemcitabine, niraparib, and pralsetinib.

At a glance

• Classification: Cancer
• Umbrella term: 14 Mondo subtypes
• Cohort genes: 4
• GWAS associations: 4
• ClinVar variants: 4
• Clinical trials: 25

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endocrine gland neoplasm
Mondo ID	MONDO:0002082
EFO	EFO:0003769
NCIT	C3010
SNOMED CT	387922007
UMLS	C0014132
MedGen	4044
Anatomy (UBERON)	UBERON:0002368
Is cancer (heuristic)	yes

Also known as: endocrine gland neoplasm (disease) · endocrine gland tumor · endocrine gland tumour · endocrine neoplasm · endocrine system neoplasm · endocrine system tumor · endocrine system tumour · endocrine tumor · endocrine tumour · malignant endocrine tumor · malignant endocrine tumour · neoplasm of endocrine gland · tumor of endocrine gland · tumour of endocrine gland

Data availability: 4 ClinVar variants · 4 GWAS associations (5 studies).

Disease family

An umbrella term covering 14 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm

Related subtypes (47): pre-malignant neoplasm, giant cell tumor, hematopoietic and lymphoid system neoplasm, skin neoplasm, mesenchymal cell neoplasm, epidural spinal canal neoplasm, skeletal muscle neoplasm, trophoblastic neoplasm, cancer, germ cell tumor, benign neoplasm, upper aerodigestive tract neoplasm, histiocytoma, embryonal neoplasm, head and neck neoplasm, epithelial neoplasm, reproductive system neoplasm, non-seminomatous lesion, odontogenic cyst, phosphaturic mesenchymal tumor, thyroglossal duct cyst, hamartoma, mesenchymoma, mesothelial neoplasm, peritoneal neoplasm, virus associated tumor, nail tumor, respiratory tract neoplasm, spindle cell neoplasm, mixed neoplasm, urinary system neoplasm, cystic neoplasm, childhood neoplasm, melanocytic neoplasm, digestive system neoplasm, nervous system neoplasm, neoplasm of thorax, connective tissue neoplasm, bronchial adenomas/carcinoids childhood, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, erythroplakia, retroperitoneal neoplasm, cardiovascular neoplasm, dermoid or epidermoid cyst of the central nervous system, connective and soft tissue neoplasm, NTRK fusion positive cancer, RET fusion positive cancer

Subtypes (14): benign endocrine neoplasm, thymus neoplasm, granulosa cell tumor, thyroid tumor, pituitary tumor, familial tumoral calcinosis, neuroendocrine neoplasm, malignant endocrine neoplasm, non-functioning endocrine neoplasm, functioning endocrine neoplasm, adrenal gland neoplasm, pineal body neoplasm, tumor of parathyroid gland, liver and intrahepatic bile duct neoplasm

Genetics & variants

GWAS landscape

4 GWAS associations across 5 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs150494521	2e-12	KDR - RN7SL822P	A	2.97
chr9:100527157	3e-12		A	0.3
rs187381978	7e-12	TMEM163	C	2.34
rs138515848	9e-12	NT5ELP	C	2.53

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475601	Verma A	2024	1,410	448,683	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479816	Verma A	2024	347	121,286	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481523	Verma A	2024	347	121,286	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90246045	Walters RG	2023	130	75,734	Genotyping and population characteristics of the China Kadoorie Biobank.
GCST90435626	Zhou W	2018	90	407,399	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	4

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	3
unknown	0

Functional consequences

Consequence	Count
intron_variant	2
intergenic_variant	1
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs150494521	4	55144369	A>G	0	intergenic_variant	KDR - RN7SL822P	2e-12	Tier 4: intronic/intergenic
chr9:100527157				0.382			3e-12	Tier 4: intronic/intergenic
rs187381978	2	134620027	C>G	0.001	intron_variant	TMEM163	7e-12	Tier 4: intronic/intergenic
rs138515848	5	64415715	C>A	0	intron_variant	NT5ELP	9e-12	Tier 4: intronic/intergenic

ClinVar germline variants

4 retrieved; paginated sample, class counts are floors:

3 conflicting classifications of pathogenicity, 1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
4072153	NM_024666.5(AAGAB):c.535+1G>T	AAGAB	Pathogenic	criteria provided, single submitter
133842	NM_024529.5(CDC73):c.412C>A (p.Pro138Thr)	CDC73	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
161294	NM_001370259.2(MEN1):c.511C>T (p.Arg171Trp)	MEN1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
241333	NM_020975.6(RET):c.1063+9G>A	RET	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 21 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
CDC73	Act	UCEC
MEN1	LoF	ACC,BLCA,BRCA,HCC,LUNG,PANCREAS,PANET,WDTC	CIViC #3485
RET	Act	ANGS,MEL,NSCLC,PGNG,SOFT_TISSUE,WDTC	CIViC #42

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CDC73	Orphanet:143	Parathyroid carcinoma
CDC73	Orphanet:99879	Familial isolated hyperparathyroidism
CDC73	Orphanet:99880	Hyperparathyroidism-jaw tumor syndrome
AAGAB	Orphanet:79501	Punctate palmoplantar keratoderma type 1
MEN1	Orphanet:2965	Prolactinoma
MEN1	Orphanet:314786	Silent pituitary adenoma
MEN1	Orphanet:314790	Null pituitary adenoma
MEN1	Orphanet:652	Multiple endocrine neoplasia type 1
MEN1	Orphanet:97279	Insulinoma
MEN1	Orphanet:99725	Pituitary gigantism
MEN1	Orphanet:99879	Familial isolated hyperparathyroidism
RET	Orphanet:146	Differentiated thyroid carcinoma
RET	Orphanet:1848	Renal agenesis, bilateral
RET	Orphanet:247698	Multiple endocrine neoplasia type 2A
RET	Orphanet:247709	Multiple endocrine neoplasia type 2B
RET	Orphanet:276621	Sporadic pheochromocytoma/secreting paraganglioma
RET	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
RET	Orphanet:388	Hirschsprung disease
RET	Orphanet:93100	Renal agenesis, unilateral
RET	Orphanet:99361	Isolated familial medullary thyroid carcinoma
RET	Orphanet:99803	Haddad syndrome

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CDC73	HGNC:16783	ENSG00000134371	Q6P1J9	Parafibromin	clinvar
AAGAB	HGNC:25662	ENSG00000103591	Q6PD74	Alpha- and gamma-adaptin-binding protein p34	clinvar
MEN1	HGNC:7010	ENSG00000133895	O00255	Menin	clinvar
RET	HGNC:9967	ENSG00000165731	P07949	Proto-oncogene tyrosine-protein kinase receptor Ret	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CDC73	Parafibromin	Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways.
AAGAB	Alpha- and gamma-adaptin-binding protein p34	May be involved in endocytic recycling of growth factor receptors such as EGFR.
MEN1	Menin	Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates ‘Lys-4’ of histone H3 (H3K4).
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN,…

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	6.9×	0.273
Other/Unknown	3	1.3×	0.404

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CDC73	Other/Unknown	no		Cdc73/Parafibromin, CDC73_C, Cdc73_N
AAGAB	Other/Unknown	no		Alpha/Gamma-adaptin-bd_p34
MEN1	Other/Unknown	no		Menin
RET	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Cadherin-like_dom

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
calcaneal tendon	1
colonic epithelium	1
sural nerve	1
islet of Langerhans	1
mucosa of transverse colon	1
rectum	1
granulocyte	1
lower esophagus mucosa	1
right hemisphere of cerebellum	1
dorsal root ganglion	1
substantia nigra pars compacta	1
substantia nigra pars reticulata	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CDC73	271	ubiquitous	marker	calcaneal tendon, sural nerve, colonic epithelium
AAGAB	282	ubiquitous	marker	islet of Langerhans, rectum, mucosa of transverse colon
MEN1	271	ubiquitous	marker	granulocyte, lower esophagus mucosa, right hemisphere of cerebellum
RET	193	broad	marker	substantia nigra pars reticulata, dorsal root ganglion, substantia nigra pars compacta

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MEN1	5,226
CDC73	4,592
RET	4,203
AAGAB	931

Intra-cohort edges

A	B	Sources
CDC73	MEN1	string_interaction
MEN1	RET	string_interaction

Structural data

PDB: 4 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MEN1	O00255	69
RET	P07949	34
CDC73	Q6P1J9	20
AAGAB	Q6PD74	3

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 38. Enrichment computed across 4 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Formation of the beta-catenin:TCF transactivating complex	2	80.1×	0.003	CDC73, MEN1
TCF dependent signaling in response to WNT	2	78.5×	0.003	CDC73, MEN1
Signaling by WNT	2	74.6×	0.003	CDC73, MEN1
Protein ubiquitination	1	271.9×	0.026	CDC73
Formation of the nephric duct	1	211.5×	0.026	RET
NPAS4 regulates expression of target genes	1	165.5×	0.026	RET
Formation of the ureteric bud	1	165.5×	0.026	RET
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1	122.8×	0.026	MEN1
RHO GTPases activate IQGAPs	1	115.3×	0.026	MEN1
Dengue virus activates/modulates innate and adaptive immune responses	1	112.0×	0.026	CDC73
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	1	102.9×	0.026	MEN1
RNA Polymerase II Transcription	2	15.0×	0.026	CDC73, MEN1
Post-translational protein modification	2	12.8×	0.026	CDC73, MEN1
Gene expression (Transcription)	2	11.9×	0.026	CDC73, MEN1
Formation of WDR5-containing histone-modifying complexes	1	88.5×	0.027	MEN1
RET signaling	1	86.5×	0.027	RET
Deactivation of the beta-catenin transactivating complex	1	77.7×	0.028	MEN1
Signaling by TGF-beta Receptor Complex	1	66.8×	0.028	MEN1
Formation of RNA Pol II elongation complex	1	64.5×	0.028	CDC73
RNA Polymerase II Transcription Elongation	1	64.5×	0.028	CDC73
E3 ubiquitin ligases ubiquitinate target proteins	1	64.5×	0.028	CDC73
Signaling by Hedgehog	1	61.4×	0.028	CDC73
Hedgehog ‘on’ state	1	52.9×	0.029	CDC73
Epigenetic regulation by WDR5-containing histone modifying complexes	1	51.4×	0.029	MEN1
Metabolism of proteins	2	8.2×	0.029	CDC73, MEN1
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	1	48.8×	0.030	MEN1
RNA Polymerase II Pre-transcription Events	1	45.9×	0.030	CDC73
Signaling by TGFB family members	1	38.5×	0.035	MEN1
CHD1 and CHD2 subfamily	1	36.2×	0.035	CDC73
Signal Transduction	2	6.8×	0.035	CDC73, MEN1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
embryonic epithelial tube formation	1	2106.5×	0.009	RET
posterior midgut development	1	2106.5×	0.009	RET
positive regulation of metanephric glomerulus development	1	1404.3×	0.009	RET
ureter maturation	1	1053.2×	0.009	RET
Peyer’s patch morphogenesis	1	1053.2×	0.009	RET
GDF15-GFRAL signaling pathway	1	1053.2×	0.009	RET
MAPK cascade	2	76.6×	0.009	MEN1, RET
positive regulation of mRNA 3’-end processing	1	842.6×	0.010	CDC73
endodermal cell fate commitment	1	702.2×	0.011	CDC73
negative regulation of cyclin-dependent protein serine/threonine kinase activity	1	526.6×	0.012	MEN1
T-helper 2 cell differentiation	1	468.1×	0.012	MEN1
lymphocyte migration into lymphoid organs	1	468.1×	0.012	RET
positive regulation of extrinsic apoptotic signaling pathway in absence of ligand	1	383.0×	0.012	RET
positive regulation of cell size	1	324.1×	0.012	RET
glial cell-derived neurotrophic factor receptor signaling pathway	1	300.9×	0.012	RET
positive regulation of cell cycle G1/S phase transition	1	280.9×	0.012	CDC73
membrane protein proteolysis	1	263.3×	0.012	RET
positive regulation of cell adhesion mediated by integrin	1	263.3×	0.012	RET
osteoblast development	1	247.8×	0.012	MEN1
neuron cell-cell adhesion	1	247.8×	0.012	RET
enteric nervous system development	1	247.8×	0.012	RET
negative regulation of myeloid cell differentiation	1	234.1×	0.012	CDC73
response to pain	1	221.7×	0.012	RET
regulation of axonogenesis	1	221.7×	0.012	RET
negative regulation of cell population proliferation	2	21.1×	0.012	CDC73, MEN1
neuron maturation	1	200.6×	0.013	RET
obsolete negative regulation of DNA-binding transcription factor activity	1	183.2×	0.014	MEN1
negative regulation of protein phosphorylation	1	145.3×	0.016	MEN1
response to gamma radiation	1	145.3×	0.016	MEN1
mRNA 3’-end processing	1	140.4×	0.016	CDC73

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Lanreotide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dexamethasone, Metformin, Trabectedin.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 3 · Undrugged: 1

Druggability breadth: 3 of 4 evidence-associated genes (75%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
MEN1	LOPERAMIDE
RET	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MEN1	475	4
RET	135	4
CDC73	1	2
AAGAB	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
LOPERAMIDE	4	MEN1
CANDESARTAN CILEXETIL	4	MEN1
EVANS BLUE FREE ACID	4	MEN1
DIENESTROL	4	MEN1
BEXAROTENE	4	MEN1
IFOSFAMIDE	4	MEN1
PROGESTERONE	4	MEN1
CLOTRIMAZOLE	4	MEN1
AMINOCAPROIC ACID	4	MEN1
LATANOPROST	4	MEN1
FLUORESCEIN	4	MEN1
OXCARBAZEPINE	4	MEN1
SALMETEROL XINAFOATE	4	MEN1
AMIODARONE HYDROCHLORIDE	4	MEN1
TRICLABENDAZOLE	4	MEN1
TRYPAN BLUE FREE ACID	4	MEN1
MIGALASTAT	4	MEN1
DROPERIDOL	4	MEN1
ARIPIPRAZOLE	4	MEN1
AMOXAPINE	4	MEN1
RALOXIFENE HYDROCHLORIDE	4	MEN1
IDARUBICIN	4	MEN1
ACETAMINOPHEN	4	MEN1
OXYBUTYNIN CHLORIDE	4	MEN1
DECAMETHONIUM BROMIDE	4	MEN1
DESLORATADINE	4	MEN1
DITHIAZANINE	4	MEN1
TRIMETREXATE	4	MEN1
NICARDIPINE HYDROCHLORIDE	4	MEN1
PROTRIPTYLINE HYDROCHLORIDE	4	MEN1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
RET	1,586	Binding:1573, Functional:10, ADMET:3
MEN1	93	Binding:86, Functional:7
CDC73	8	Binding:8

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
RET	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
RET	1,586

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
LOPERAMIDE	4	MEN1
CANDESARTAN CILEXETIL	4	MEN1
EVANS BLUE FREE ACID	4	MEN1
DIENESTROL	4	MEN1
BEXAROTENE	4	MEN1
IFOSFAMIDE	4	MEN1
PROGESTERONE	4	MEN1
CLOTRIMAZOLE	4	MEN1
AMINOCAPROIC ACID	4	MEN1
LATANOPROST	4	MEN1
FLUORESCEIN	4	MEN1
OXCARBAZEPINE	4	MEN1
SALMETEROL XINAFOATE	4	MEN1
AMIODARONE HYDROCHLORIDE	4	MEN1
TRICLABENDAZOLE	4	MEN1
TRYPAN BLUE FREE ACID	4	MEN1
MIGALASTAT	4	MEN1
DROPERIDOL	4	MEN1
ARIPIPRAZOLE	4	MEN1
AMOXAPINE	4	MEN1
RALOXIFENE HYDROCHLORIDE	4	MEN1
IDARUBICIN	4	MEN1
ACETAMINOPHEN	4	MEN1
OXYBUTYNIN CHLORIDE	4	MEN1
DECAMETHONIUM BROMIDE	4	MEN1
DESLORATADINE	4	MEN1
DITHIAZANINE	4	MEN1
TRIMETREXATE	4	MEN1
NICARDIPINE HYDROCHLORIDE	4	MEN1
PROTRIPTYLINE HYDROCHLORIDE	4	MEN1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	MEN1, RET
B	Phased (≥1) drug, not yet approved	1	CDC73
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	AAGAB

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
AAGAB	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 25.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	13
PHASE2	6
PHASE3	2
PHASE1/PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00353496	PHASE3	COMPLETED	Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
NCT01964430	PHASE3	COMPLETED	Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the Apact Study)
NCT03412877	PHASE2	RECRUITING	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT00050414	PHASE2	COMPLETED	A Study of Trabectedin in Patients With Advanced Ovarian Cancer
NCT00180960	PHASE2	TERMINATED	Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
NCT03037385	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03535727	PHASE1/PHASE2	COMPLETED	A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
NCT03562897	PHASE2	COMPLETED	Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
NCT03717298	PHASE2	COMPLETED	Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
NCT04556071	PHASE2	UNKNOWN	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
NCT02897778	PHASE1	COMPLETED	Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02909452	PHASE1	COMPLETED	Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT01005654	Not specified	RECRUITING	Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
NCT01109394	Not specified	RECRUITING	Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT01763125	Not specified	RECRUITING	Establishment of a Tumor Bank for Blood Samples
NCT01789229	Not specified	RECRUITING	Establishment of a Tumor Bank for Tissue Samples
NCT03410394	Not specified	RECRUITING	Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)
NCT04493632	Not specified	RECRUITING	OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
NCT04949282	Not specified	RECRUITING	Spanish Series of Patients Treated With the Radionuclide Lutetium177
NCT05974696	Not specified	RECRUITING	A Research Registry on Aggressive PitNETs
NCT07606287	Not specified	NOT_YET_RECRUITING	Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
NCT01621295	Not specified	COMPLETED	Assessing the Patient Experience in Cancer Care
NCT02330497	Not specified	COMPLETED	Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor
NCT05022667	Not specified	COMPLETED	Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy
NCT05152927	Not specified	COMPLETED	Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GEMCITABINE	4	2
NIRAPARIB	4	1
PRALSETINIB	4	1
TRABECTEDIN	4	1
ENTINOSTAT	3	2
CHEMBL4297597	0	1